MetLife president acquires 115 dividend shares

MetLife’s U.S. Business president increased his directly held MET common shares via dividend reinvestment on deferred compensation.

Rhea-AI Filing Summary

METLIFE INC (MET) reported that Ramy Tadros, President, U.S. Business, acquired 115 shares of common stock on September 8, 2026 through a grant/award transaction. The shares reflect imputed reinvestment of dividends on deferred shares under the MetLife Leadership Deferred Compensation Plan, bringing his directly held common shares to 212,695.

Insider Trade Summary

Grant/Award: 115 shares

Grant/Award 1 txn

Insider TADROS RAMY

Role President, U.S. Business

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	115	$95.50	$11K

Holdings After Transaction: Common Stock — 212,695 shares (Direct)

Footnotes (1)

1. F1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Leadership Deferred Compensation Plan. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the reporting person has deferred.

Key Figures

Shares acquired: 115 shares Attributed price per share: $95.50 per share Shares held after transaction: 212,695 shares +1 more

4 metrics

Shares acquired 115 shares Grant/award acquisition reported for September 8, 2026

Attributed price per share $95.50 per share Imputed reinvestment of dividends on deferred shares

Shares held after transaction 212,695 shares Direct ownership of MetLife common stock after the September 8, 2026 award

Transaction date September 8, 2026 Date of reported grant/award acquisition

Key Terms

Imputed reinvestment of dividends, Deferred shares, MetLife Leadership Deferred Compensation Plan

3 terms

Imputed reinvestment of dividends financial

"Imputed reinvestment of dividends on deferred shares pursuant to the MetLife"

Deferred shares financial

"Deferred shares represent shares of MetLife, Inc. common stock that have"

Deferred shares are a class of stock whose economic benefits or certain shareholder rights are delayed or paid later than ordinary shares—for example, dividends may be paid only after other shareholders receive theirs, or voting or redemption rights may be postponed. For investors, that timing difference matters because deferred shares typically offer lower near-term income and different risk, affecting expected returns, priority in payouts, and the share’s market value; think of them like a delayed paycheck compared with a regular salary.

MetLife Leadership Deferred Compensation Plan financial

"pursuant to the MetLife Leadership Deferred Compensation Plan. Deferred shares"

FAQ

What insider transaction did MET report for Ramy Tadros on September 8, 2026?

MET reported that Ramy Tadros received a grant/award of 115 shares of MetLife common stock on September 8, 2026, reflecting imputed reinvestment of dividends on deferred shares under the MetLife Leadership Deferred Compensation Plan.

At what price were the new MET shares attributed in the Tadros Form 4?

The 115 MetLife (MET) shares reported for Ramy Tadros were attributed at $95.50 per share, consistent with the imputed reinvestment of dividends on deferred shares under the company’s leadership deferred compensation plan.

How many MET shares does Ramy Tadros hold after this reported transaction?

After the September 8, 2026 transaction, Ramy Tadros is reported as directly holding 212,695 shares of MetLife common stock, including the 115 shares acquired through dividend reinvestment on deferred shares.

What is the nature of the MET shares acquired by Ramy Tadros in this filing?

The filing states the 115 MET shares represent imputed reinvestment of dividends on deferred shares under the MetLife Leadership Deferred Compensation Plan. They are common stock that had become payable, but receipt of which he has deferred.

Was the Tadros MET transaction made under a Rule 10b5-1 trading plan?

No. The Form 4 indicates the Rule 10b5-1 checkbox is not marked, and there is no footnote stating that the September 8, 2026 acquisition of 115 MET shares was made pursuant to a Rule 10b5-1 trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:03 PM Accepted by SEC EDGAR 09/10/2026 - 04:02 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

TADROS RAMY

(Last) (First) (Middle)

METLIFE, INC.

200 PARK AVENUE

(Street)

NEW YORK NEW YORK 10166

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
METLIFE INC [ MET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President, U.S. Business

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/08/2026		A(1)		115	A	$95.5	212,695	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Imputed reinvestment of dividends on deferred shares pursuant to the MetLife Leadership Deferred Compensation Plan. Deferred shares represent shares of MetLife, Inc. common stock that have become payable, but receipt of which the reporting person has deferred.

Remarks:

	/s/ Morgan Keehner-Jones Mayes, Attorney-in-fact	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)